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Dilated cardiomyopathyAbstract Background: The effect of cardiac resynchronization therapy (CRT) on functional
mitral regurgitation (FMR) is reﬂected on both clinical and echocardiographic response. We sought
to assess the behavior of FMR and the response to CRT implantation in relation to the baseline
width of the QRS complex among patients with dilated cardiomyopathy (DCM).
Patients and methods: This is a prospective observational case-control study, including forty
patients with advanced DCM who had left bundle branch block (LBBB), QRSP 130 ms (group
1) and 10 patients with QRS < 130 ms (group 2) both with echocardiographic evidence of dyssyn-
chrony and subjected to CRT in our center.
Results: Evidence of response to CRT at 6 months, was observed in 31 patients (77.5%) of group 1
Vs 2 (20%) patients of group 2 (p. 0.001). MR improvement was higher among responders to CRT
in 31/33 (93.9%) Vs 2/17 patients (11.7%) of the non responders (p. 0.003). FMR improvement was
observed in 31 patients of group 1 (77.5%) Vs 2 patients of group 2 (20%) p. value 0.001.
Conclusion: Among patients with DCM, the degree of FMR regression after CRT seems to be
more clear in patients with a baseline QRS width P130 ms and this seems to be associated with
better response of the patients to CRT.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.1. Introduction
Mitral regurgitation (MR) with a structurally normal valve is
often encountered among patients with heart failure in up to
30%. The presence and degree of functional mitral regurgita-
tion (FMR) in heart failure patients is an important factor
affecting both symptomatology and survival among patients
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nism of functional MR is mainly lack of leaﬂet cooptation sec-
ondary to disturbed balance between the closing forces and the
tethering forces.2 Surgery is one of the therapeutic options, but
several recent studies demonstrated that cardiac resynchroni-
zation therapy (CRT) might also be able to reduce functional
MR.3 The inﬂuence of CRT on mitral regurgitation is one of
the factors affecting the degree of response of the patient
and degree of both clinical and echocardiographic improve-
ment after resynchronization.4,5 On the other hand, the re-
sponse of mitral regurgitation to Cardiac resynchronization
therapy (CRT) may be variable and may be related to the
mechanism of the regurgitation itself.6 FMR was previously
reported to be more prevalent among patients with wide
QRS complex more than 130 ms.7
2. Aim of the work
We sought to assess the behavior of mitral regurgitation and its
relation to clinical and echocardiographic response to CRT
implantation among patients with advanced DCM and systolic
heart failure selected for CRT due to wide QRS complex
(P130 ms), LBBB and echocardiographic evidence of dyssyn-
chrony Vs patients with QRS complex <130 ms, selected accord-
ing to echocardiographic evidence of LV dyssynchrony.
3. Patients and methods
This is a prospective observational case-control study that in-
cluded all patients with advanced systolic heart failure despite
optimal medical therapy at least moderate mitral regurgitation
subjected to CRT implantation in the electrophysiology (EP)
laboratory of Saud Albabtain cardiac center, Al-Dammam,
KSA in the period between May 2009 and July 2012. The pa-
tients were segregated into two groups according to criteria of
dyssynchrony used for selection of the patients for CRT
implantation: the 1st groups were selected according to stan-
dard criteria with LBBB, wide QRS complex P130 ms and
echocardiographic evidence of dyssynchrony, the 2nd group
included patients with QRS complex <130 ms and mechanical
dyssynchrony as assessed by echocardiographic parameters.
Ischemic heart disease was ruled out either by myocardial per-
fusion imaging or by coronary angiography.
3.1. Inclusion criteria
Age >18 years, sinus rhythm, NYHA class III–IV heart failure
despite optimal medical treatment for at least 3 months, LV ejec-
tion fraction (EF) less than 35%, idiopathic dilated cardiomyop-
athy, functional mitral regurgitation of at least moderate degree
(Pgrade2), indicator of dyssynchrony either: (a) standard electri-
cal criteria in the form of wide QRS complexP130 ms, left bun-
dle branch block (LBBB) with echocardiographic evidence of
dyssynchrony in group 1 (or) (b) echocardiographic evidence of
interventricular or intraventricular mechanical delay in patients
with narrow QRS complex <130 ms.
3.2. Exclusion criteria
Patients with any of the following were excluded from our
study: patients with ischemic cardiomyopathy, hypertrophic,restrictive, obstructive cardiomyopathy, organic and hemody-
namically signiﬁcant structural valve disease (deﬁned as valvu-
lar stenosis greater than mild, and/or organic valvular
regurgitations), primary pulmonary hypertension, uncorrected
congenital heart disease, patient candidates for heart surgery,
stroke that occurred within 6 weeks prior the study enrollment,
pregnant women, patients with right bundle branch block
(RBBB), patients with end-stage co-morbidities affecting their
expected survival or refusal to give the informed consent and
any patient who did not complete at least 6 months of regular
follow up in our center post implantation.
3.2.1. All included patients were subjected to
Full history and clinical evaluation, 12 lead ECG and chest X-
ray. Patients received all appropriate treatments for HF, which
included a diuretic, an ACE-inhibitor, or an angiotensin receptor
blocker, a beta-blocker (BB) and if needed digitalis. Doses of
these background medications were kept maximized during the
follow-up period. Ivabradine is also used in our center in heart
failure patients with a heart rate above 70 B/min despite maxi-
mum tolerated BB according to the ﬁndings of the SHIFT trial.8
3.2.2. Echocardiographic assessment protocol
Standard echocardiography, including Doppler studies, was
performed (Vivid 7, Vingmed-General Electric, USA). The
LV volumes and ejection fraction were assessed by biplane
Simpson’s equation using the apical 4-chamber and 2-chamber
views.
3.2.2.1. Measurements. LV size was evaluated by measuring
the end-diastolic and end-systolic diameters (EDD, ESD in
cm) in 2D parasternal short-axis view images and calculating
the end-diastolic and end-systolic volumes (EDV, ESV in ml)
using Simpson formula. LV systolic function was evaluated
using both the ejection fractions (EF, %) calculated from
volumes.9
3.2.2.2. MR severity evaluation. The severity of mitral regurgita-
tion was graded semi-quantitatively from color-ﬂow Doppler in
the conventional parasternal long-axis and apical 4-chamber
images. Mitral regurgitation was characterized as: mild = 1+
(jet area/left atrial area < 10%), moderate = 2+ (jet area/left
atrial area 10–20%), moderately severe = 3+ (jet area/left atrial
area 20–45%), and severe = 4+ (jet area/left atrial
area > 45%). In addition, grading according to mitral regurgi-
tant volume was calculated by volumetric method to conﬁrm
and compare its amount quantitatively. Mitral regurgitation
was characterized as: mild = 1+ (regurgitant volume < 30 ml/
beat), moderate = 2+ (regurgitant volume 30–44 ml/beat),
moderately severe = 3+ (regurgitant volume 45–59 ml/beat),
and severe = 4+ (regurgitant volumeP 60 ml/beat).10,11
3.2.3. Dyssynchrony indexes were calculated as follows
3.2.3.1. M-mode indexes. Septal-to-posterior wall motion delay
(cut-off value = 130 ms): measurement was obtained from the
M-mode tracing of the LV as the time interval between the
maximal inward motion of the septum and the left posterior
wall.12
3.2.3.2. Tissue Doppler imaging (TDI) time intervals and
indexes13. For TDI analysis, the digital cine loops were
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Electric –– Vingmed, Milwaukee, WI, USA) by 2 independent
observers, blinded to the clinical outcome. The sample volume
was placed in the LV basal portions of the anterior, inferior,
septal and lateral walls (using the 2- and 4-chamber images),
and per region, the time interval between the onset of the
QRS complex and the peak systolic velocity and peak strain
was derived as follows:
Time to peak velocity, including the post-ejection period: the
interval from onset of the QRS to the maximum positive veloc-
ity, including the period after aortic valve closure. Time to peak
strain: the interval fromonset of theQRS to peak negative strain
throughout the cardiac cycle, including post-systolic shortening.
Septal and lateral basal segments in the apical four-chamber
view are compared and dyssynchrony is present when the delay
in activation of opposite walls is more than 65 ms.
3.2.4. Speckle tracking dyssynchrony analysis14
Speckle-tracking analysis for each of the 6 segments of the
mid-ventricle short-axis view, the time to peak radial strain
was measured. Then, the radial strain DYS (cut-off va-
lue = 130 ms) index was calculated as the difference between
earliest and latest time to peak strain.
We categorized patients as having echocardiographic evi-
dence of dyssynchrony only with strong and at least two echo-
cardiographic parameters denoting dyssynchrony.
3.2.5. Biventricular device implantation
Biventricular devices were implanted endovascularly via left or
right subclavian veins in all but two patients (an epicardial left
ventricular lead was inserted). The LV pacing lead was inserted
into either the lateral or postero-lateral cardiac vein, in only
one case it was positioned in the antero-lateral position. An
epicardial left ventricular lead was inserted in two patients,
which was due to inability to cannulate the coronary sinus
and one of them had dextrocardia. The LV lead connected
to the lateral wall epicardially was passed through an inter-cos-
tal space and connected to the device in the subclavian area
with the right atrial and ventricular leads inserted via subcla-
vian vein. Of the included 50 patients, 41 patients received
an Attain system (over-the-wire, Medtronic Inc) 23 of them re-
ceived biventricular cardiac deﬁbrillators (InSync Marquiz,
ICD, Medtronic), 5 received evices of St. Jude Inc. and 4 re-
ceived the Easytrak over-the-wire lead (Guidant Inc.).
3.2.6. Programming and follow up
The biventricular pacemaker was programmed in DDD mode
with biventricular pacing. Adjustment of the atrio-ventricular
delaywas performed to ensure the longest possible atrio-ventric-
ular ﬁlling time evaluated frompulsedDoppler analysis of trans-
mitral LV ﬁlling to maximize LV ﬁlling and ejection times. The
interventricular interval was programmed at 0 interval basically
and later optimized according to ECG and Echo evidence of
synchronization. Before CRT implantation, after 24 h, one
month, 3-month and at 6-month follow-up, echocardiographic
assessment of LV volumes and EF was performed, and the clin-
ical status, including NYHA functional class were assessed.
3.2.6.1. Response to CRT was assessed after 6 months of CRT
as follows. CRT response: was deﬁned as NYHA class
improvement by at least one grade and echocardiographicevidence of LV reverse remodeling at 6 months. Successful
LV reverse remodeling was deﬁned as a reduction of LV
end-systolic volume of >15%, and increase in EF by >10%.15
CRT non-response: death from cardiac causes or failure to
reach the above pre-speciﬁed NYHA class and echocardio-
graphic changes.
The degree of MR was assessed initially before implanta-
tion and graded from 0 to 4/4 and re-assessed regularly at fol-
low-up intervals. The change in functional MR was correlated
with the outcome in both groups.
The study protocol was approved by the scientiﬁc commit-
tee, and written informed consents were obtained from all the
patients.
4. Statistical analysis
Continuous variables are expressed as mean ± SD. Categori-
cal data are summarized as frequencies and percentages. Dif-
ferences in continuous variables between responders and
non-responders were analyzed using independent sample ‘‘t’’
test and x2 or Fisher’s exact tests were used for dichotomous
variables as appropriate. A p-value of 60.05 was considered
statistically signiﬁcant.
5. Results
This prospective observational study included 50 patients (39
males), with dilated cardiomyopathy and EF less than 35%
and advanced systolic heart failure that had CRT implantation
in our center and completed at least 6 months of follow up in
our center post implantation. The 1st group included 40 pa-
tients (31 males) aged 52.4 ± 10.5 years who had wide QRS
complexP130 ms (157.87 ± 21.5 ms) and LBBB morphology.
The 2nd group included 10 patients (8 males) aged
55.3 ± 8.5 years with a QRS < 130 ms (97.5 ± 15.1 ms). All
patients were in functional class III/IV who were on optimal
medical treatment for at least 3 months. The base line clinical
characteristics showed no signiﬁcant difference except in the
presence of DM which was signiﬁcantly higher in group 1
(70%) Vs in group 2 (30%) p. 0.03. All patients were on opti-
mal medical therapy (Table 1).
During the follow up period post CRT implantation, 66%
(33/50) of all patients fulﬁlled the pre-deﬁned criteria of re-
sponse to CRT. Clinical response was detected in 34 patients
of group 1, thirty-one of them (91%) showed echocardio-
graphic response so overall 31 patients fulﬁlled the deﬁnition
of CRT responder in group 1 (77.5%) while in group 2, three
patients showed clinical response with only 2 of them showing
echocardiographic response and hence two patients (20%) of
group 2 were considered CRT responders with a strong asso-
ciation of clinical and echocardiographic response among all
patients (p. < 0.001) and signiﬁcantly more responders in
group 1 Vs group 2 (p. value 0.001). Reduction of LVESV
was highly more signiﬁcant (18.9 ± 8.07%) in group one Vs
group 2 (1.93 ± 12.03%). The medians of reduction of
LVESV in the 2 groups (wide and narrow QRS) were 19.88
and 6.72, respectively. We ran a Mann–Whitney’s U test
which showed that there was a statistically signiﬁcant differ-
ence between the 2 groups; U= 44, Z= 3.78, p= 0.0. Also
improvement of EF in group 1 from 20.61 ± 6.45% before to
32.18 ± 7.3 after CRT was found to be signiﬁcantly more than
Table 1 Demographic Data of the included patients in both groups.
Variable Group I (40) Group II (10) P
Age in years (mean ± SD) 52.38 ± 10.49 55.3 ± 8.5 0.4
Male sex, No. (%) 31 (77.5%) 8 (80%) 1.0
HTN 19 (47.5%) 4 (40%) 0.7
DM 28 (70%) 3 (30%) 0.03
Dyslipidemia 20 (50%) 4 (40%) 0.7
Smoking 25 (62.5%) 6 (60%) 1.0
Obesity 10 (25%) 6 (60%) 0.56
COPD 6 (15%) 3 (30%) 0.35
Family history 8 (20%) 4 (40%) 0.22
Drugs
BB, No. (%) 35 (87.5%) 8 (80%) 0.6
Diuretics, No. (%) 33 (82.5%) 9 (90%) 1.0
ACEI –, No. (%) 33 (82.5%) 9 (90%) 1.0
ARBs, No. (%) 4 (10%) 1 (10%) 1.0
Spironolactone, No. (%) 27 (67.5%) 3 (30%) 0.06
Ivabradine 10 (25%) 4 (40%) 0.4
Digoxin 6(15%) 2(20%) 0.6
HTN, hypertension; DM, diabetes mellitus; COPD, chronic obstructive pulmonary disease; BB, beta blockers; ACEI, angiotensin converting
enzyme inhibitors; ARBs, angiotensin receptor blocker.
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CRT) with a p. value of <0.001.
Responders to CRT were found to have signiﬁcantly more
MR improvement (from grade 2.3 ± 0.5 before to 1.4 ± 0.9
post CRT) Vs non responders (from 2.3 ± 0.6 to 2.1 ± 1.2)
(p. value = 0.03) (Table 2). The medians of reduction of MR
grade improvement in the 2 groups (wide and narrow QRS)
were 1 and 1, respectively. We ran a Mann–Whitney’s U test
which showed that there was a statistically signiﬁcant differ-
ence between the 2 groups; U= 75, Z= 3.21, p= 0.001.
The medians of reduction of MR volume Difference in the 2
groups (wide and narrow QRS) were 17 and 13.5, respec-
tively. We ran a Mann–Whitney’s U test which showed that
there was a statistically signiﬁcant difference between the 2
groups; U= 72, Z= 3.107, p= 0.002. MR improvement
was observed in 31 (77.5%) of the wide QRS patients com-
pared to 2 patients (20%) of the narrow QRS patients
(p= 0.001).
MR improvement was associated with good response to
CRT in 29/31 (93.5%) of group 1 and 2/2 (100%) of the
responders of group 2 with a highly signiﬁcant relation be-
tween MR improvement and response to CRT (31 of 33
responders versus 2 of 17 non responders, p. < 0.001). There
was a more signiﬁcant improvement in the grade of MR in
group 1 [from grade 2.3 ± 0.6 (MR volume: 40.8 ± 8.9) to
1.5 ± 1.0 (MR volume: 25.8 ± 15.8)] after CRT than in group
2 [from grade 2.1 ± 0.3 (37.9 ± 7.6 ml) to grade 2.5 ± 0.9
(43.2 ± 10.13 ml)] with a p value = 0.01 (Fig. 1, Table 2).
The improvement of FMR was early within the 1st month
in 21 patients of the wide complex group (52.5%) and none of
the narrow QRS complex patients (p. = 0.002). This improve-
ment of MR was so early in 8 patients to be observed within
the 1st 24 h as shown in Fig. 2. Late improvement was ob-
served in 10 patients (25%) of the wide complex group and
in the two patients of the narrow QRS patients. So early
improvement represented 21/33 (64%) of the cases of MR
improvement and was exclusively in the wide QRS complex
patients.Deterioration of FMR was observed in 11/17 patients who
had non improvement of MR. Deterioration of FMR after
CRT implantation was observed in seven out of the ten pa-
tients with QRS < 130 ms (70%) Vs 4 out of 40 patients
(10%) with wide QRS and all of them were non responders
to CRT with a p. value < 0.001. Two patients died of pump
failure during the follow up period, both belonged to the group
2 and both were non responders with deteriorating FMR.
6. Discussion
CRT in patients with advanced systolic dysfunction is associ-
ated with a non response rate of around 30%.16 This is similar
to the overall outcome of our patients. In our studied popula-
tion, among patients with dilated cardiomyopathy and ad-
vanced systolic heart failure, responders to CRT during the
study period represented 66% (33/50) of all patients. Clinical
response was highly associated with echocardiographic re-
sponse and few cases of clinical but no echocardiographic re-
sponse may be related to placebo effect.
The follow up of our patients after CRT implantation
showed that among patients with wide QRS complex
P130 ms and LBBB, the degree of MR improvement was sub-
stantial and signiﬁcantly more than patients with narrower
QRS complex. The higher percentage of responders among
the wide QRS patients (77.5%) was accompanied with a simi-
larly signiﬁcant higher percentage of patients with MR
improvement 77.5% with earlier and signiﬁcantly more
improvement of FMR (from grade 2.3 ± 0.6 to 1.5 ± 1.0
and 25.8 ± 15.8 ml after CRT) and vice versa, the much less
percentage of responders in the narrower QRS group (20%)
was associated with a low percentage of MR improvement
(20%) even with deterioration of the MR (from grade
2.1 ± 0.3 before to 2.5 ± 0.9 after) (p. value: 0.001).
Regarding the QRS width, our ﬁndings are actually concor-
dant to most of the previous large trials in the literature. A
signiﬁcant treatment interaction with QRS duration was
observed in MADIT-CRT and RAFT, and a trend toward
Table 2 Functional status, QRS width and echocardiographic parameters of the included patients in both groups before and after
CRT.
Variable Group I (40) Group II (10) P
NYHA functional class before 3.22 ± 0.42 3.20 ± 0.42 0.8
NYHA functional class after 2.25 ± 0.74 3.00 ± 0.81 0.02
Mean QRS width before 157.87 ± 21.5 97.5 ± 15.1 <0.001
Mean QRS width after 101.25 ± 11.07 99.5 ± 9.55 0.6
LVESV before (mean ± SD) 211.93 ± 42.46 202.9 ± 60.1 0.584
LVESV after (mean ± SD) 172.63 ± 42.65 206.7 ± 66.13 0.050
Reduction of LVESV (mean ± SD) (%) 18.9 ± 8.07 1.93 ± 12.03 0.0
LVEDV before (mean ± SD) 268.63 ± 56.84 242.3 ± 66.96 0.212
LVEDV after (mean ± SD) 255.23 ± 57.65 253.6 ± 64.7 0.938
EF before (mean ± SD) 20.61 ± 6.45 16.5 ± 6.36 0.077
EF after (mean ± SD) 32.18 ± 7.3 19.41 ± 8.74 0.000
EF improvement (mean ± SD) (%) 11.57 ± 5.12 2.91 ± 8.84 0.000
MR grade before (mean ± SD) 2.33 ± 0.57 2.1 ± 0.32 0.239
MR grade After (mean ± SD) 1.48 ± 1.01 2.5 ± 0.85 0.005
MR grade improvement (mean ± SD) 0.93 ± 0.89 0.4 ± 1.07 U= 75, Z = 3.21, p= 0.001
MR volume before 40.8 ± 8.9 37.9 ± 7.6 0.3
MR volume after 25.8 ± 15.8 43.2 ± 10.13 0.002
MR volume diﬀerence 15.0 ± 14.4 5.3 ± 15.9 U= 72, Z= 3.107, p= 0.002
Echo responder, No. (%) 31 (77.5%) 2 (20%) 0.001
Clinical responder No. (%) 34(85%) 3(30%) 0.001
Responders (both clinical and echocardiographic) 31 (77.5%) 2 (20%) 0.001
MR improvement, No. (%) 31 (77.5%) 2 (20%) 0.001
Early MR improvement 21 (52.5%) 0 (0%) 0.02
MR deterioration No. (%) 4 (10%) 7 (70%) 0.0003
LVESV, left ventricular end systolic volume; LVEDV, left ventricular end diastolic volume; EF, ejection fraction; MR, mitral regurgitation.
Figure 1 A comparison of the echocardiographic parameters of the patients before and after CRT implantation in group 1 with wide
QRS complex and group II with narrow QRS. (LVESV: left ventricular end systolic volume, EF: ejection fraction, Pts: patients, MR:
mitral regurgitation).
Mitral Regurgitation Response to Cardiac Resynchronization 339an interaction was observed in REVERSE QRS subgroup
ﬁndings.17 On the other hand, the presence of an echocardio-
graphic evidence of dyssynchrony with narrow QRS complex
is not well established as a parameter of selecting patients
for CRT implantation except for in case reports or small stud-
ies.18,19 Large multicenter randomized trials as the Rethin Q
trial20 and the ESTEEM-CRT21 trial, provided evidence that
patients with heart failure and narrow QRS intervals may
not beneﬁt from CRT if echocardiographic parameters of dys-
synchrony are used alone for selecting the patients for CRT.
Oyenuga et al. compared two groups of wide (>130 ms) andborderline (<130 ms) QRS systolic heart failure and reported
that a smaller proportion of borderline QRS duration patients
(53%) were EF responders to CRT compared with 75% with
widened QRS (p< 0.05).22 We used the same values of QRS
width in subdividing our patients and found a similar discrep-
ancy in response to CRT between patients with QRSP 130 ms
and those below 130 ms.
An important factor inﬂuencing the heart failure patient’s
outcome is the presence of signiﬁcant FMR.1 Its improvement
is one of the important factors in the clinical and echocardio-
graphic improvement of the patient with dilated cardiomyop-
Figure 2 (A) on the left side shows: up is the 12 lead ECG before the CRT implantation and below is an echocardiographic image of the
4 chamber view with left ventricular dilatation and functional mitral regurgitation (FMR) (grade 3). On the right side (B) up: is the same
patient’s ECG post CRT implantation with narrowing of the QRS and below is her echocardiography in the same apical 4 chamber view
showing reduction of LV size and disappearance of the FMR (grade 0–1) only 24 h post implantation.
340 S. Atta et al.athy and heart failure after CRT implantation. The improve-
ment of FMR is expected to decrease LVEDV, LVESV, de-
crease back ﬂow to the left atrium, decrease PASP, increase
forward cardiac output and effective EF. Previous reports by
Verhart and his colleagues23 showed that the reversal of
FMR was associated with reverse cardiac remodeling and im-
proved outcomes. Their study included patients with DCM
and basically wide QRS complex (162 ± 28 ms) and the pa-
tients with moderately severe to severe MR before CRT expe-
rienced relatively more reverse remodeling than patients with
lesser degrees of MR.
The suggested mechanisms for FMR in patients with left
ventricular systolic dysfunction are the decrease in the trans-
mitral pressure force which impairs effective mitral valve clo-
sure, the geometrical changes in the mitral annulus, papillary
muscle, mitral valve, and the dyssynchronus left ventricular
and papillary muscle contractions.24,25 Increased intraventricu-
lar electrical delay, indicated by prolongation of QRS dura-
tion, plays a role in the development of FMR. In a previous
study, moderate to severe FMR was found to be more com-
mon in patients with a QRS duration P130 ms which may
indicate a relation of this level of QRS width and FMR.7 In
our current study we included patients with at least moderate
MR and compared patients with width of the QRSP 130 ms
versus patients with QRS < 130 ms to ﬁnd out whether this
width of QRS in the presence of LBBB can anticipate the
MR reversal by CRT.
In our study, the reduction of the degree of MR was early
in two thirds of the improved cases and all patients with early
improvement belonged to the wide QRS group. Kanzaki
et al.26 demonstrated a signiﬁcant reduction in FMR severity
in the early period after CRT among patients with LBBBand QRS duration 168 ± 30 ms (regurgitant volume decreased
from 40 ± 20 ml to 24 ± 17 ml p< 0.01). Similarly, Breit-
hardt and his colleagues studied heart failure patients who
were candidates for CRT and had LBBB, and the severity of
FMR was found to improve immediately after CRT, with a
reduction in effective regurgitant oriﬁce area (ERO) from
25 ± 19 mm2 to 13 ± 8 mm2 (p< 0.01).27 Ypenburg et al.
re-evaluated 25 patients with regressed FMR in the acute per-
iod after CRT again after 6 months. After temporary interrup-
tion of CRT, acute loss of papillary muscle resynchronization
and acute recurrence of FMR was seen. The patients selected
for CRT in their study also had LBBB and wide QRS.28 The
improvement of MR was more prominent in the acute phase
after CRT but it continued in the long term with reverse
remodeling of the ventricle. These reports support our similar
results of early and sometimes immediate improvement of MR
even before LV signiﬁcant reverse remodeling. This may de-
note a direct reversal of the mechanism of MR by CRT in pa-
tients with wide QRS complex and LBBB before LV reverse
remodeling.
Turner et al.,29 previously reported an improvement in syn-
chronization and mitral regurgitation among patients with
narrow QRS duration as well as patients with LBBB morphol-
ogy using biventricular and LV pacing. Many differences in
patients’ criteria make it difﬁcult to compare our results to
their results. They included ischemic as well as DCM patients
and included only 14 patients with DCM while all our 50 pa-
tients were of the DCM category. Also they did not aim to in-
clude patients with signiﬁcant MR as we did. In their narrow
QRS patients with improvement, there was an evidence of elec-
trical delay by intra-cardiac recording despite the normal QRS
duration which means that those patients have not only
Mitral Regurgitation Response to Cardiac Resynchronization 341mechanical delay but also an electrical delay (occult electrical
dyssynchrony) which may explain the improvement by CRT.
We did not assess for intra-cardiac electrical delay in our
patients.
In another report by Yu et al.,30 they have studied the CRT
effect on 51 patients of wide Vs a similar number of narrowQRS
complex with advanced systolic heart failure of both ischemic
and non ischemic origin and reported that both clinical, EF
and FMR improvement were similar among both groups given
that they had a similar coexisting mechanical asynchrony by
TDI at baseline. However, these reported data involved both
ischemic and non ischemic patients without discrimination in
the results and outcome so we ﬁnd it difﬁcult to compare them
to our pure DCM patients. Also the degree of FMR was mild
to moderate, its presence was not a pre-requisite for inclusion
of the patients in the study by Yu et al., and the LVESV was
120–144 ± 70 cc unlike our patients who all had at least moder-
ate to severe FMR and remarkably higher LVESV (200–
210 ± 60 cc). These differences between the patient populations
may explain the different outcomes between the study ofYu and
his colleagues and our study. In addition, the reports of Turner
et al. and Yu et al. are not concordant with the results of the
above mentioned large randomized trials that did not support
the value of echocardiographic parameters for patient selection
for CRT among narrow QRS patients.20,21
Choi et al. studied the role of mechanical dyssynchrony on
FMR in patients with dilated cardiomyopathy using real time
3D echocardiography.31 The dyssynchrony index was not a
signiﬁcant determinant of the effective regurge oriﬁce (ERO)
on the multivariate model. Displacement of the anterior papil-
lary muscle and consequent MV tenting remained the strongest
determinants of the degree of ERO. These ﬁndings suggested
that the distorted geometric change of the LV with MV tenting
is a necessary condition for the development of FMR, whereas
mechanical dyssynchrony could have a minor role. However,
in the study by Choi and colleagues, the included patients
had a mild degree (ERO= 0.17 ± 0.10 cm2) of FMR and a
small percentage of them had wide QRS complex and left bun-
dle branch block (18%) as compared to the previous studies.32
In our opinion, this small percentage of included patients with
wide QRS and LBBB may explain the lack of correlation of
dyssynchrony with FMR in this study. FMR may be multifac-
torial with variable contribution to its pathogenesis in different
patient categories. FMR that is correctable by CRT may be
more linked to dyssynchrony 2ry to signiﬁcant electrical delay
(wide QRS) with LBBB.
Deterioration of FMR was a clear ﬁnding in our group II
patients with narrower QRS who showed more signiﬁcant
deterioration (70%) of FMR than group I (Wide QRS group)
(10%), p. value = 0.0003. In narrow QRS patients, CRT
implantation may add to the geometry distortion and may in-
crease or induce dyssynchrony due to distortion of the electri-
cal activation instead of its correction, this may disturb more
the closing mechanism of the mitral valve and thus may even
cause deterioration of the FMR and worsen the outcome
among the narrow QRS patients.7. Conclusion
Among patients with dilated cardiomyopathy, the degree of
FMR regression after CRT seems to be more clear in patientswith a baseline QRS widthP130 ms and this seems to be asso-
ciated with better response of the patients to CRT. The pres-
ence of signiﬁcant FMR at baseline among patients with
DCM, and QRS < 130 may be associated with deterioration
and worse outcome after CRT implantation.
8. Limitations
The limited number of included patients especially among the
narrow QRS group limits the statistical value of our results
and larger studies are required to study narrow QRS patients
with MR.
Our study did not include detailed assessment of geometri-
cal factors contributing to FMR among patients of the two
categories of patients and the changes after CRT implantation.
Studying such parameters in future studies pre and post CRT
may give more light on the relation of FMR to cardiac dyssyn-
chrony and its reversal.
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